SenTriparna Icahn School of Medicine at Mount SinaiUnited States

Dr. Triparna Sen is an Associate Professor of Oncological Sciences and Director of the Lung Cancer PDX Platform at the Icahn School of Medicine at Mount Sinai, New York. Her groundbreaking research focuses on the biology of lung cancer initiation, progression, and drug resistance, uncovering therapeutic vulnerabilities to advance treatment outcomes. Dr. Sen has made transformative contributions to understanding molecular subsets of lung cancer, particularly small cell lung cancer (SCLC). Her pioneering work identified DNA damage response (DDR) proteins as critical therapeutic targets, demonstrating that DDR inhibition not only combats SCLC but also enhances antitumor immunity through innate immune signaling. Recently, she uncovered molecular mechanisms driving the transformation of non-small cell lung cancer (NSCLC) to SCLC during therapy resistance, paving the way for innovative approaches to overcome resistance. Her work has directly supported multiple clinical trials in SCLC, where she has also co-led efforts in biomarker identification. She plays a pivotal role in leading SCLC clinical trials, ensuring the translation of her discoveries into patient care. Recently, her research on ATR and lurbinectedin and how it modulates the immune microenvironment has had direct clinical implications, further solidifying her impact in the field. Her accomplishments are particularly remarkable for a relatively young investigator. Her accomplishments have been recognized with numerous prestigious awards, including the AAAS Martin and Rose Wachtel Cancer Research Award (2021), 40 Under 40 in Cancer: Emerging Leaders Award (2020), and several AACR Scholar Awards. She has secured independent funding from leading organizations such as the NIH/NCI, DoD, LCRF, and IASLC and has published over 60 peer-reviewed articles in high-impact journals. As a leader in the field, Dr. Sen has been appointed to key roles, including Conference Co-Chair 2025 Meeting: Unraveling Precancer and Early-stage Lung Cancer: From Biology to Clinical Application (2025), Conference Co-Chair of the IASLC Small Cell Lung Cancer Meeting (2021), Session Chair for IASLC Hot Topics on SCLC (2023), and Program Committee Member for major IASLC conferences in 2023, 2024, and 2025. Dr. Sen is also deeply committed to mentoring the next generation of researchers, fostering a culture of scientific curiosity, innovation, and excellence. Her guidance has empowered many emerging scientists to advance their careers and make meaningful contributions to oncology research.